logo
Honey and allergy relief: Do these two really go together?

Honey and allergy relief: Do these two really go together?

Fox News30-04-2025

Spring is in the air – and so are seasonal allergies.
"Spring can feel like a breath of fresh air, unless you're one of the millions dealing with seasonal allergies," said Dr. Joseph Mercola, a board-certified family physician based in Ormond Beach, Florida. "While trees bloom and flowers bud, you're left battling itchy eyes, sneezing fits or sinus pressure. If that sounds familiar, you're not alone."
As many allergy sufferers seek help from alternative remedies, some scientific studies indicate that honey may indeed help relieve some of the pesky discomforts of seasonal allergies – although the research is far from definitive.
Honey has health benefits because of its unique chemical composition, C. Marina Marchese told Fox News Digital.
"It's a botanical fingerprint of a particular time and place, with potential wellness benefits that go far beyond the kitchen," said Marchese, founder of the American Honey Tasting Society in Weston, Connecticut.
Honey might help with seasonal allergies, but the evidence is mixed.
"Critics point out that the pollen found in honey mostly comes from flowers, while the kind that triggers your allergies is usually airborne from trees, grasses or weeds," Mercola told Fox News Digital. "Bees don't typically gather that kind in large amounts."
A 2002 study by researchers at the University of Connecticut found no significant symptom relief in people with allergic rhino conjunctivitis after taking local or clover honey daily for 30 weeks.
However, Mercola cited other studies that suggest honey does have anti-allergic potential.
"In a 2021 mini-review published in Frontiers in Pharmacology, researchers examined both animal and human studies. In mice and rat models, honey reduced common allergy symptoms like sneezing, nasal rubbing and airway inflammation — pointing to a possible protective effect in controlled settings," he said.
"In human trials, including one involving patients with allergic rhinitis, those who consumed Tualang honey saw a steady improvement in nasal congestion and sneezing, even after they stopped using antihistamines."
The type of honey you consume matters, according to Mercola.
"Clinical and preclinical research suggests that honeys like Tualang and Manuka may offer more potent anti-allergy effects," he said. "These varieties are rich in bioactive compounds like gallic acid, caffeic acid and kaempferol, which have been shown to dampen inflammatory pathways and reduce histamine release."
Marchese also stresses the importance of avoiding commercial honey, pasteurized or ultra-filtered honey, which "lacks the pollens, enzymes and other beneficial compounds that might be helpful."
Many honeys sold commercially in supermarkets are not the best quality of honey, Marchese told Fox News Digital, and are imported from various countries and blended, treated with heat at high temperatures and compromising the integrity of the honey.
If honey is going to offer any potential benefit for allergies, Marchese said, it should be fresh, preferably from a backyard beekeeper, unheated and unfiltered.
Even if honey doesn't eliminate your allergies completely, it offers other wellness benefits, Marchese said.
"It's rich in antioxidants, has antibacterial properties and can help soothe sore throats and coughs," she said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Your favorite alcoholic beverage could be linked to deadly form of cancer, study finds
Your favorite alcoholic beverage could be linked to deadly form of cancer, study finds

Yahoo

time16 hours ago

  • Yahoo

Your favorite alcoholic beverage could be linked to deadly form of cancer, study finds

Following the surgeon general's January advisory linking alcohol consumption to seven types of cancer, a new study from the International Agency for Research on Cancer (IARC) has revealed another possible risk. The research, recently published in the journal PLOS Medicine, classified alcohol as a carcinogen, highlighting a particular increased risk of pancreatic cancer. The surgeon general's previous advisory named cancers of the breast (in women), colorectum, esophagus, voice box, liver, mouth and throat. Psychedelics As Potential Mental Health Treatment Are Explored By Trump Administration The researchers associated the pancreatic cancer risk with beer and spirits/liquor, but not with the intake of wine. "Alcohol consumption is a known carcinogen, but until now, the evidence linking it specifically to pancreatic cancer has been considered inconclusive," said senior study author Dr. Pietro Ferrari, head of the IARC Nutrition and Metabolism Branch, in a press release. Read On The Fox News App "Our findings provide new evidence that pancreatic cancer may be another cancer type associated with alcohol consumption, a connection that has been underestimated until now." For the study, researchers recruited 2.5 million participants with a median age of 57, following them for about 16 years. Fda Approves First Ai Tool To Predict Breast Cancer Risk Out of the group, 10,067 cases of pancreatic cancer were recorded. Each increase of 10 grams of ethanol per day in alcohol consumption was associated with a 3% increase in the risk of pancreatic cancer, the study found. Women who consumed 15 to 30 grams of alcohol (about one to two standard drinks) per day had a 12% increase in pancreatic cancer risk. Men who consumed 30 to 60 grams (two to six standard drinks) per day had a 15% increased risk of pancreatic cancer, and intake of over 60 grams per day was associated with a 36% greater risk. The research did have some limitations. "This observational study examined alcohol intake evaluated at a single time point during mid-to-late adulthood and included a limited number of Asian cohorts," the researchers wrote. "Further research is needed to better understand the role of lifetime alcohol consumption — for example, during early adulthood — and the influence of specific consumption patterns, such as binge-drinking." Dr. Adam Scioli, an addiction psychiatrist at Caron Treatment Centers in Pennsylvania, previously commented to Fox News Digital that "alcohol is a toxin." "There have been reports for years that it could be beneficial for one's health — but we know now that alcohol ingestion is one of the modifiable risk factors for cancer," Scioli, who is not affiliated with IARC, told Fox News Digital. Click Here To Sign Up For Our Health Newsletter Dr. Marc Siegel, senior medical analyst for Fox News, was not involved in the study but spoke with Fox News Digital about the findings. "This is in keeping with alcohol as a toxin that directly inflames and damages pancreatic cells," he said. Around 75,000 Americans each year are diagnosed with a cancer that is in some way linked to alcohol use, according to Scioli. Dr. Neha Pathak, WebMD's chief physician editor of health and lifestyle medicine, noted that the study highlights a new, independent risk factor for pancreatic cancer. "What's important to know is that there really isn't a safe level of drinking when it comes to cancer risk," Atlanta-based Pathak, who also did not participate in the research, told Fox News Digital. For more Health articles, visit "This study reinforces that message — but it also shows how complex these links are, and how we need to keep digging deeper into the role of alcohol and different drinking habits in cancer development," she added. Fox News Digital reached out to several beverage industry associations requesting comment. Melissa Rudy of Fox News Digital contributed to this article source: Your favorite alcoholic beverage could be linked to deadly form of cancer, study finds

Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration

Yahoo

time18 hours ago

  • Yahoo

Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration

Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial barrier This proof-of-concept study provides compelling support for the selected dosing regimen of MTx's investigational BK polyomavirus-neutralizing antibody Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or 'MTx'), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development. The study reports that, 0.015% (median) of the serum concentration of therapeutic antibody rituximab is found in the urine, with levels reaching up to 4.2%. These findings suggest that therapeutic IgG antibodies can cross the kidney filtration barrier in measurable amounts, challenging prior assumptions about size-exclusion limitations and supporting the feasibility of antibody-based interventions for renal infections. Christoph Esslinger, CSO of MTx, commented: 'This data reinforces the notion that potravitug can access infected renal tissue and supports the continued development of this first-in-class candidate for the treatment of BK viremia in kidney transplant recipients.' BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term graft survival. Despite this, therapeutic options remain limited, partly due to the prevailing belief that large-molecule biologics cannot effectively penetrate kidney tissue. This study contributes to a growing body of evidence suggesting otherwise. MTx is currently conducting a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA for the treatment of BK viremia in kidney transplant recipients, with top line results anticipated later in 2025. The full publication can be accessed here. -Ends- Contacts Memo Therapeutics AG info@ ICR Healthcare Amber Fennell, Ashley Tapp memotx@ +44 (0)20 3709 5700 About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become a first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn. Alongside potravitug, MTx is focused on discovering novel oncology targets. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on in to access your portfolio

Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration

Yahoo

time18 hours ago

  • Yahoo

Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration

Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial barrier This proof-of-concept study provides compelling support for the selected dosing regimen of MTx's investigational BK polyomavirus-neutralizing antibody Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or 'MTx'), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development. The study reports that, 0.015% (median) of the serum concentration of therapeutic antibody rituximab is found in the urine, with levels reaching up to 4.2%. These findings suggest that therapeutic IgG antibodies can cross the kidney filtration barrier in measurable amounts, challenging prior assumptions about size-exclusion limitations and supporting the feasibility of antibody-based interventions for renal infections. Christoph Esslinger, CSO of MTx, commented: 'This data reinforces the notion that potravitug can access infected renal tissue and supports the continued development of this first-in-class candidate for the treatment of BK viremia in kidney transplant recipients.' BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term graft survival. Despite this, therapeutic options remain limited, partly due to the prevailing belief that large-molecule biologics cannot effectively penetrate kidney tissue. This study contributes to a growing body of evidence suggesting otherwise. MTx is currently conducting a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA for the treatment of BK viremia in kidney transplant recipients, with top line results anticipated later in 2025. The full publication can be accessed here. -Ends- Contacts Memo Therapeutics AG info@ ICR Healthcare Amber Fennell, Ashley Tapp memotx@ +44 (0)20 3709 5700 About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become a first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn. Alongside potravitug, MTx is focused on discovering novel oncology targets. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store